title: Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing.
authors.affiliation: aTropical and Infectious Diseases Unit, Royal Liverpool University Hospital bWellcome Trust Liverpool Glasgow Centre for Global Health Research cDepartment of Paediatric Infectious Diseases, Alder Hey Children's Foundation NHS Trust dDepartment of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Lewis
authors.forename: Eimear
authors.initials: E
authors.lastname: Railton
authors.forename: Andrew
authors.initials: A
authors.lastname: Riordan
authors.forename: Saye
authors.initials: S
authors.lastname: Khoo
authors.forename: Mas
authors.initials: M
authors.lastname: Chaponda
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D005312:Fetal Blood / Q000187:drug effects; D019983:Guideline Adherence; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D010078:Oxazines; D010879:Piperazines; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011256:Pregnancy Outcome; D011297:Prenatal Exposure Delayed Effects; D011728:Pyridones; D055815:Young Adult; D000099226:Dolutegravir
chemical_list: D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir